TY - JOUR T1 - Baricitinib restrains the immune dysregulation in COVID-19 patients JF - medRxiv DO - 10.1101/2020.06.26.20135319 SP - 2020.06.26.20135319 AU - Vincenzo Bronte AU - Stefano Ugel AU - Elisa Tinazzi AU - Antonio Vella AU - Francesco De Sanctis AU - Stefania Canè AU - Veronica Batani AU - Rosalinda Trovato AU - Alessandra Fiore AU - Varvara Petrova AU - Francesca Hofer AU - Roza Maria Barouni AU - Chiara Musiu AU - Simone Caligola AU - Laura Pinton AU - Lorena Torroni AU - Enrico Polati AU - Katia Donadello AU - Simonetta Friso AU - Francesca Pizzolo AU - Manuela Iezzi AU - Federica Facciotti AU - Piergiuseppe Pelicci AU - Daniela Righetti AU - Paolo Bazzoni AU - Mariaelisa Rampudda AU - Andrea Comel AU - Walter Mosaner AU - Claudio Lunardi AU - Oliviero Olivieri Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/30/2020.06.26.20135319.abstract N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia associated with lymphocytopenia and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small molecules. Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19. Indeed, we demonstrate a significant reduction in serum levels of interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)α, a rapid recovery in circulating T and B cell frequencies and an increased antibody production against SARS-CoV-2 spike protein in baricitinib-treated patients. Moreover, treated patients underwent a rapid reduction in oxygen flow need and progressive increase in the P/F. Our work provides the basis on developing effective treatments against COVID-19 pathogenesis using on-target therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04438629Funding StatementThis work was supported by Fondazione Cariverona (ENACT Project) and Fondazione TIM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review board of Azienda Ospedaliera Universitaria di Verona Prot. n.17963 (25 March 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding authors upon reasonable request. ER -